KRIT1: A Potential Drug Target and Biomarker (G889)
KRIT1: A Potential Drug Target and Biomarker
KRIT1, or Ku7001, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the karyin gene family, which is characterized by the presence of a unique ankyrin repeating unit. Recent studies have identified KRIT1 as a potential drug target and biomarker, with potential therapeutic applications in a variety of diseases.
The ankyrin repeat unit is a special domain on the KRIT1 protein. This domain is a repeating sequence composed of four amino acid units, including two conserved alanine residues. Alanine is a common amino acid that plays important biological functions in organisms, including participating in signal transmission, metabolic regulation, and cell proliferation. In addition, alanine is also an important drug target in drug research. There are already many target drugs that exert their effects by inhibiting alanine metabolism.
Therefore, KRIT1, as a protein with unique characteristics, is considered a potential drug target. In order to further study the pharmacological effects of KRIT1, scientists have conducted a large number of studies. These findings indicate that KRIT1 has broad application prospects in drug research, especially in the treatment of neurological diseases.
First, KRIT1 has potential applications in treating neurodegenerative diseases. Neurodegenerative diseases are a type of disease caused by the death or damage of nerve cells, such as Parkinson's disease, Alzheimer's disease, etc. These diseases cause the patient's nerve cells to die, resulting in severe decline in motor and cognitive abilities. Currently, there are no effective treatments for many neurodegenerative diseases, so studying KRIT1 as a drug target is of great significance.
Secondly, KRIT1 also has potential applications in the treatment of cardiovascular diseases. Cardiovascular disease is a type of disease caused by the death or damage of heart muscle cells, such as myocardial infarction, heart attack
Protein Name: KRIT1 Ankyrin Repeat Containing
Functions: Component of the CCM signaling pathway which is a crucial regulator of heart and vessel formation and integrity (By similarity). Negative regulator of angiogenesis. Inhibits endothelial proliferation, apoptosis, migration, lumen formation and sprouting angiogenesis in primary endothelial cells. Promotes AKT phosphorylation in a NOTCH-dependent and independent manner, and inhibits ERK1/2 phosphorylation indirectly through activation of the DELTA-NOTCH cascade. Acts in concert with CDH5 to establish and maintain correct endothelial cell polarity and vascular lumen and these effects are mediated by recruitment and activation of the Par polarity complex and RAP1B. Required for the localization of phosphorylated PRKCZ, PARD3, TIAM1 and RAP1B to the cell junction, and cell junction stabilization. Plays a role in integrin signaling via its interaction with ITGB1BP1; this prevents the interaction between ITGB1 and ITGB1BP1. Microtubule-associated protein that binds to phosphatidylinositol 4,5-bisphosphate (PIP2)-containing membranes in a GTP-bound RAP1-dependent manner. Plays an important role in the maintenance of the intracellular reactive oxygen species (ROS) homeostasis to prevent oxidative cellular damage. Regulates the homeostasis of intracellular ROS through an antioxidant pathway involving FOXO1 and SOD2. Facilitates the down-regulation of cyclin-D1 (CCND1) levels required for cell transition from proliferative growth to quiescence by preventing the accumulation of intracellular ROS through the modulation of FOXO1 and SOD2 levels. May play a role in the regulation of macroautophagy through the down-regulation of the mTOR pathway (PubMed:26417067)
The "KRIT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRIT1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86
